CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery

Title:CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery

Volume: 17 Issue: 4

Author(s): Francis Robert, Sidong Huang and Jerry Pelletier*

Affiliation:

• Department of Biochemistry, McGill University, Montreal, QC, H3G 1Y6,Canada

Keywords: CRISPR/Cas9, Drug discovery, Target: drug interaction validation, Base editing, Druggable genome, RNA.

Abstract: Introduction: The ability of most laboratories to easily access CRISPR/Cas9 engineering tools has caused a revolution in biology. One of the areas that will continue to be impacted by genome editing is the drug discovery process.

Objective: CRISPR/Cas9 will not only serve to accelerate the drug discovery pipeline, but also streamline line it by identifying high-value targets, facilitating the validation of drug: target interactions and mechanisms of action, and stimulating the development of phenotype-based high throughput screens as alternatives to target-based assays.

Conclusion: We review the literature and hurdles that have been overcome to develop the current generation of tools being used to enrich the drug discovery paradigm.

Cite this article as:

Robert Francis , Huang Sidong and Pelletier Jerry *, CRISPR/Cas9 Editing to Facilitate and Expand Drug Discovery, Current Gene Therapy 2017; 17 (4) . https://dx.doi.org/10.2174/1566523217666171121164615